Zydus Lifesciences Limited is showing strong bullish momentum backed by consistent earnings growth, a robust product pipeline, and regulatory approvals in key global markets. Technically, the stock has broken out of a consolidation phase and is trading above key moving averages, indicating strength. Buying at ₹903 offers a favorable risk-reward setup with an upside target of ₹997, representing nearly 10% potential gains. The stop-loss is set at ₹814 to manage downside risk effectively. Positive developments in the specialty and biosimilars segments further support upside potential. This trade aligns with current sector strength and institutional accumulation trends in pharma.
BUY : ZYDUSLIFE-EQ( ZYDUSLIFE ) [7929]
—
by